The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, the gravity of unmet medical needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Environmental Sustainability in Pharmaceuticals: Anti-malarial peptides.
According to GlobalData’s Technology Foresights, which uses over 756,000 patents to analyse innovation intensity for the pharmaceutical industry, there are 110 innovation areas that will shape the future of the industry.
Anti-malarial peptides is a key innovation area in environmental sustainability
Anti-malarial peptides exhibit activity on malaria parasites, Plasmodium spp., either in blood or mosquito stages, or both. The range of natural and synthetic molecules that make up these peptides is broad, with differences in size, charge, hydrophobicity, and secondary structural characteristics. The activity of anti-malarial peptides is influenced by several environmental variables, including pH, metal ions, and proteases.
GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 30+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of anti-malarial peptides.
Key players in anti-malarial peptides– a disruptive innovation in the pharmaceutical industry
‘Application diversity’ measures the number of different applications identified for each relevant patent and broadly splits companies into either ‘niche’ or ‘diversified’ innovators.
‘Geographic reach’ refers to the number of different countries each relevant patent is registered in and reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.
Patent volumes related to anti-malarial peptides
| Company | Total patents (2010 - 2021) | Premium intelligence on the world's largest companies |
| GSK | 121 | Unlock company profile |
| U.S. Department of Defense | 52 | Unlock company profile |
| Inovio Pharmaceuticals | 39 | Unlock company profile |
| Fraunhofer-Gesellschaft zur Forderung der Angewandten Forschung | 34 | Unlock company profile |
| Centre National de la Recherche Scientifique | 28 | Unlock company profile |
| Zydus Lifesciences | 28 | Unlock company profile |
| SuZhou SJ Biomaterials | 28 | Unlock company profile |
| United States Of America | 24 | Unlock company profile |
| VLP Therapeutics | 24 | Unlock company profile |
| Ligand Pharmaceuticals | 24 | Unlock company profile |
| Johnson & Johnson | 22 | Unlock company profile |
| Abbott Laboratories | 20 | Unlock company profile |
| Otsuka Holdings | 17 | Unlock company profile |
| CAS-Lamvac Biotech | 16 | Unlock company profile |
| Institut Pasteur | 16 | Unlock company profile |
| United Biomedical | 14 | Unlock company profile |
| Seattle Children's Hospital | 10 | Unlock company profile |
| Statens Serum Institut | 10 | Unlock company profile |
| Theravectys | 10 | Unlock company profile |
| Rhode Island Hospital | 9 | Unlock company profile |
| Vac-4-All | 9 | Unlock company profile |
| Edwards Lifesciences | 8 | Unlock company profile |
| Fundacio Cellex | 8 | Unlock company profile |
| Hospital for Sick Children | 7 | Unlock company profile |
| Sumitomo Chemical | 7 | Unlock company profile |
| Eisai | 7 | Unlock company profile |
| Oxford BioMedica | 7 | Unlock company profile |
| Hawaii Biotech | 7 | Unlock company profile |
| US Government | 6 | Unlock company profile |
| Catalan Institution for Research and Advanced Studies | 6 | Unlock company profile |
| IMV | 5 | Unlock company profile |
| Henry M. Jackson Foundation for the Advancement of Military Medicine | 5 | Unlock company profile |
| US Department of Health and Human Services | 5 | Unlock company profile |
| Centre de Recerca en Salut Internacional de Barcelona | 5 | Unlock company profile |
| Sumaya Biotech | 5 | Unlock company profile |
Source: GlobalData Patent Analytics
GSK is a leading healthcare company that focuses on developing, manufacturing and commercialising pharmaceuticals, vaccines and consumer healthcare products. It offers drugs for the treatment of diseases such as HIV, respiratory, cancer, immuno-inflammation, anti-viral, central nervous system (CNS), metabolic, cardiovascular and urogenital, anti-bacterial, dermatological, and certain rare diseases. GSK and Medicines for Malaria Venture (MMV) together have developed a preclinical portfolio of antimalarial properties. Through its extensive global R&D and supply network, GSK offers clinical, regulatory, and manufacturing knowledge and resources when compounds enter the clinical development stage. In 2021, the WHO recommended broader use of GSK’s Mosquirix to reduce illness and deaths from malaria in children living in sub-Saharan Africa and other regions with moderate to high transmission as defined by the WHO.
To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical.
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox